Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus

Masahiro Matsuki(Eisai (Japan)), Yasuhiro Funahashi(Eisai (United States))

Cancer Science

January 20, 2017

10.1111/cas.13169

Cited by 65

Related Papers

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

|Journal of Thyroid Research|2014|479

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

|PLoS ONE|2019|458

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

|Cancer Medicine|2018|258

Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy

|Scientific Reports|2020|59

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitor

|Cancer Science|2014|39